Tumor budding is an independent prognostic factor in stage III colon cancer patients: A post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).

Fiche publication

Date publication

mars 2022

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François , Dr VERNEREY Dewi , Dr DERANGERE Valentin , Mr FALCOZ Antoine

Tous les auteurs :
Basile D, Broudin C, Emile JF, Falcoz A, Pagès F, Mineur L, Bennouna J, Louvet C, Artru P, Fratte S, Ghiringhelli F, André T, Derangère V, Vernerey D, Taieb J, Svrcek M,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35306156

Résumé

Histological characteristics at the invasive front may reflect tumor aggressiveness; specifically, tumor budding (Bd) is an emerging prognostic biomarker in colon cancer (CC). We explored further the significance of Bd for risk stratification by evaluating survival of stage III CC patients included in the IDEA-France phase III trial.